Shopping Cart
Remove All
Your shopping cart is currently empty
Synonyms:


| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $98 | - | In Stock | |
| 5 mg | $289 | - | In Stock | |
| 10 mg | $463 | - | In Stock | |
| 25 mg | $747 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $298 | - | In Stock |
| Description | Ganoderic acid DM is an antiandrogenic inhibitor of osteoclastogenesis that markedly suppresses the expression of c-Fos and nuclear factor of activated T cells c1 (NFATc1). The suppression mediated by Ganoderic acid DM results in the inhibition of dendritic cell-specific transmembrane protein (DC-STAMP) expression and a consequent reduction in osteoclast fusion. Ganoderic acid DM is therefore of considerable interest for mechanistic investigations involving osteoclast differentiation, bone remodeling, and androgen-associated signaling pathways in musculoskeletal research models. |
| In vitro | Ganoderic acid DM effectively inhibited cell proliferation and colony formation in MCF-7 human breast cancer cells, which was much stronger than that of MDA-MB-231 breast cancer cells. Ganoderic acid DM both concentration- and time-dependently mediated G1 cell cycle arrest and significantly decreased the protein level of CDK2, CDK6, cycle D1, p-Rb and c-Myc in MCF-7 cells. Moreover, GADM obviously induced DNA fragmentation and cleavage of PARP which are the characteristics of apoptosis and decreased the mitochondrial membrane potential in MCF-7 cells. Besides, we also showed that GADM elicited DNA damage as measured by comet assay which is a sensitive method for DNA damage detection. γ-H2AX, a marker of DNA damage, was also slightly up-regulated after treated with GADM for 6h, suggesting that the G1 cell cycle arrest and apoptosis induced by GADM may be partially resulted from GADM-induced DNA damage[1] |
| Molecular Weight | 468.67 |
| Formula | C30H44O4 |
| Cas No. | 173075-45-1 |
| Smiles | C[C@]12C3=C([C@]4(C)[C@@](CC3=O)(C(C)(C)C(=O)CC4)[H])CC[C@]1(C)[C@@]([C@@H](CC/C=C(/C(O)=O)\C)C)(CC2)[H] |
| Relative Density. | no data available |
| Storage | Keep away from direct sunlight, Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 40 mg/mL (85.35 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | |||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 µL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.